News
2 minute read

MBHB Partner Kevin Noonan Quoted in Seattle Times Article Entitled, "FDA halts trial of cancer drug by Seattle’s CTI BioPharma after patients die"

Kevin E. Noonan, Ph.D.February 10, 2016

McDonnell Boehnen Hulbert & Berghoff LLP partner Dr. Kevin Noonan is quoted in a February 10, 2016 online edition of Seattle Times in an article entitled, “FDA halts trial of cancer drug by Seattle’s CTI BioPharma after patients die.” The Food and Drug Administration has shut down Seattle-based CTI BioPharma’s clinical trial of a blood cancer drug after patients died from “intracranial hemorrhage, cardiac failure and cardiac arrest.” View the article